Biomérieux performed an internal investigation.Instrument issue was excluded as qcv results conformed to specifications.Biomérieux also performed investigational testing with vidas lyme igg, lot 1007040560/191112-0.This included testing four internal sera and the returned customer sample.The internal testing included two negative and two low positive tests; all internal results were within specifications.The customer sample also obtained a positive result when tested internally.The customer sample was then rerun with the cmg igg assay, first without sample and then without spr; both results were negative with a result of less than or equal to 4 ua/ml, duplicating the customer's initial discrepant result.The investigation concluded the most likely cause of the false negative result was operator error due to absence of spr or sample.According the above data , the reagent vidas cmv igg lot 1007040560/ 191112-0 was within the expected performance specifications.
|
A customer in the (b)(6) notified biomérieux of discrepant results associated with the vidas® cmv igg 60 tests (reference 30204, lot 1007040560).Product reference 30204 is not marketed, sold or distributed in the united states.The u.S.Similar product is reference 30204-01.On (b)(6) 2019 , the customer provided biomérieux with information regarding false negative results for a patient sample.The original result was less than 4 ua/ml, the sample was repeated and a result of 44ua/ml was obtained.The customer confirmed the incorrect test result had no adverse impact to the patient's state of health but did note a one day delay of obtaining test results.Product reference 30204 is not marketed, sold or distributed in the united states.The u.S.Similar product is reference 30204-01.
|